Inhibikase reports 2024 net loss $27.5M; cash $97.5M; PAH trial progress, new leadership

Inhibikase Therapeutics, Inc.

Net loss $27.5M ($1.16 per share) vs $19.1M ($3.16 per share) in 2023; R&D $17.2M, SG&A $11.4M.
Cash, cash equivalents and marketable securities $97.5M as of December 31, 2024.
Closed $110M private placement in October 2024 (up to $275M if warrants exercised).
Appointed Mark Iwicki CEO, Chris Cabell President & Head of R&D, John Adams CSO; added new board members.
Received Study May Proceed letter for Phase 2b trial of IkT-001 in PAH in September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.